Zai Lab Limited

Informe acción NasdaqGM:ZLAB

Capitalización de mercado: US$1.6b

Salud financiera de hoja de balance de Zai Lab

Salud financiera controles de criterios 5/6

Zai Lab tiene un patrimonio de los accionistas total de $796.1M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $1.0B y $240.2M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$806.45m
PatrimonioUS$796.12m
Total pasivoUS$240.18m
Activos totalesUS$1.04b

Actualizaciones recientes sobre salud financiera

Recent updates

A Risky Bet: Zai Lab's Uncertain Future

Apr 16

Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

Mar 29
Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Mar 24
We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S

Jan 18
Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S

Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation

Sep 22
Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation

Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 24
Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth

Jun 02
We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth

Is Zai Lab Limited (NASDAQ:ZLAB) Trading At A 44% Discount?

Feb 16
Is Zai Lab Limited (NASDAQ:ZLAB) Trading At A 44% Discount?

Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans

Jan 20
Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans

We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth

Sep 19
We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth

Zai Lab GAAP EPS of -$0.14 beats by $0.92, revenue of $48.17M beats by $1.04M

Aug 09

China accepts Zai Lab's biologics license application for neuromuscular disorder drug

Jul 13

Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth

Jun 03
Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth

As Losses Narrow, Is Zai Lab Finally Finding Its Winning Formula?

May 18

Zai Lab Revenue Triples As It Struggles To Break Cycle Of Mounting Losses

Mar 08

Bearish: Analysts Just Cut Their Zai Lab Limited (NASDAQ:ZLAB) Revenue and EPS estimates

Mar 06
Bearish: Analysts Just Cut Their Zai Lab Limited (NASDAQ:ZLAB) Revenue and EPS estimates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($939.6M) de ZLAB superan a sus pasivos a corto plazo ($203.1M).

Pasivo a largo plazo: Los activos a corto plazo de ZLAB ($939.6M) superan a sus pasivos a largo plazo ($37.1M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: ZLAB está libre de deudas.

Reducción de la deuda: ZLAB no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 1.5%.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ZLAB tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si ZLAB tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.


Descubre empresas con salud financiera